X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with ALEMBIC LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ALEMBIC LTD - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ALEMBIC LTD IPCA LABS/
ALEMBIC LTD
 
P/E (TTM) x 38.4 119.3 32.2% View Chart
P/BV x 2.9 4.4 66.5% View Chart
Dividend Yield % 0.2 0.3 68.9%  

Financials

 IPCA LABS   ALEMBIC LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-17
ALEMBIC LTD
Mar-16
IPCA LABS/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs64353 1,217.8%   
Low Rs50329 1,716.0%   
Sales per share (Unadj.) Rs254.44.7 5,390.4%  
Earnings per share (Unadj.) Rs16.18.8 183.2%  
Cash flow per share (Unadj.) Rs29.89.0 330.7%  
Dividends per share (Unadj.) Rs1.000.15 666.7%  
Dividend yield (eoy) %0.20.4 47.8%  
Book value per share (Unadj.) Rs194.627.7 701.7%  
Shares outstanding (eoy) m126.20267.03 47.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.38.7 25.9%   
Avg P/E ratio x35.74.7 762.0%  
P/CF ratio (eoy) x19.24.6 422.0%  
Price / Book Value ratio x2.91.5 198.9%  
Dividend payout %6.21.7 364.0%   
Avg Mkt Cap Rs m72,30010,962 659.6%   
No. of employees `00013.3NA-   
Total wages/salary Rs m6,960238 2,924.3%   
Avg. sales/employee Rs Th2,413.5NM-  
Avg. wages/employee Rs Th523.2NM-  
Avg. net profit/employee Rs Th152.4NM-  
INCOME DATA
Net Sales Rs m32,1061,260 2,547.5%  
Other income Rs m226264 85.6%   
Total revenues Rs m32,3321,524 2,121.4%   
Gross profit Rs m4,44883 5,371.7%  
Depreciation Rs m1,73061 2,816.8%   
Interest Rs m2410 80,266.7%   
Profit before tax Rs m2,703285 948.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m0-32 0.0%   
Tax Rs m6756 11,068.9%   
Profit after tax Rs m2,0282,343 86.6%  
Gross profit margin %13.96.6 210.9%  
Effective tax rate %25.02.1 1,166.6%   
Net profit margin %6.3185.9 3.4%  
BALANCE SHEET DATA
Current assets Rs m17,3401,689 1,026.8%   
Current liabilities Rs m9,559486 1,966.1%   
Net working cap to sales %24.295.4 25.4%  
Current ratio x1.83.5 52.2%  
Inventory Days Days100217 46.2%  
Debtors Days Days5781 70.2%  
Net fixed assets Rs m20,7791,624 1,279.4%   
Share capital Rs m252534 47.3%   
"Free" reserves Rs m24,4995,960 411.0%   
Net worth Rs m24,5537,404 331.6%   
Long term debt Rs m3,517104 3,372.4%   
Total assets Rs m39,5958,010 494.3%  
Interest coverage x12.2950.7 1.3%   
Debt to equity ratio x0.10 1,017.0%  
Sales to assets ratio x0.80.2 515.4%   
Return on assets %5.729.3 19.6%  
Return on equity %8.331.6 26.1%  
Return on capital %10.531.3 33.5%  
Exports to sales %48.62.9 1,652.4%   
Imports to sales %14.228.9 49.3%   
Exports (fob) Rs m15,61737 42,095.4%   
Imports (cif) Rs m4,571364 1,256.8%   
Fx inflow Rs m15,61737 42,095.4%   
Fx outflow Rs m5,828365 1,596.9%   
Net fx Rs m9,790-328 -2,986.1%   
CASH FLOW
From Operations Rs m2,764346 799.8%  
From Investments Rs m-1,432-48 3,007.8%  
From Financial Activity Rs m-1,591-301 528.7%  
Net Cashflow Rs m-259-3 8,626.7%  

Share Holding

Indian Promoters % 45.9 64.0 71.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.2 5,700.0%  
FIIs % 25.3 9.7 260.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 26.1 66.7%  
Shareholders   36,892 54,701 67.4%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   TORRENT PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Crash in Bitcoin, Correction in MidCap and SmallCap Indices and Top Stocks in Action Today(Pre-Open)

The past year has seen the BSE MidCap and BSE SmallCap indices surging by 43.1% and 57.1% respectively. Taking a two year view these indices have produced mind-boggling return of 75.3% .

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jan 16, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS